MAPT and amyloidosis: Concurrent with the beneficial outcomes in tau distribution, the amyloid plaque population, volume, and overall load were also significantly decreased, yet the effect was less pronounced, and not statistically significant, when an immunological assay (ELISA) was employed to assess amyloid load.